These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
237 related articles for article (PubMed ID: 20378421)
21. Higher tobramycin concentration and vibrating mesh technology can shorten antibiotic treatment time in cystic fibrosis. Coates AL; Denk O; Leung K; Ribeiro N; Chan J; Green M; Martin S; Charron M; Edwardes M; Keller M Pediatr Pulmonol; 2011 Apr; 46(4):401-8. PubMed ID: 21438171 [TBL] [Abstract][Full Text] [Related]
22. Long-term benefits of inhaled tobramycin in children with cystic fibrosis: first clinical observations from Poland. Stelmach I; Korzeniewska A; Stelmach W Respiration; 2008; 75(2):178-81. PubMed ID: 17435382 [TBL] [Abstract][Full Text] [Related]
23. Antibiotic treatment of chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. Møller NE; Høiby N Scand J Infect Dis Suppl; 1981; 29():87-91. PubMed ID: 6458884 [TBL] [Abstract][Full Text] [Related]
24. Pseudomonas aeruginosa antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI). Oermann CM; McCoy KS; Retsch-Bogart GZ; Gibson RL; McKevitt M; Montgomery AB J Antimicrob Chemother; 2011 Oct; 66(10):2398-404. PubMed ID: 21784781 [TBL] [Abstract][Full Text] [Related]
25. Tobramycin inhalation powder in cystic fibrosis patients: response by age group. Geller DE; Nasr SZ; Piggott S; He E; Angyalosi G; Higgins M Respir Care; 2014 Mar; 59(3):388-98. PubMed ID: 23983274 [TBL] [Abstract][Full Text] [Related]
26. Safety of inhaled (Tobi®) and intravenous tobramycin in young children with cystic fibrosis. Hennig S; McKay K; Vidmar S; O'Brien K; Stacey S; Cheney J; Wainwright CE J Cyst Fibros; 2014 Jul; 13(4):428-34. PubMed ID: 24565869 [TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics and safety of tobramycin administered by the PARI eFlow rapid nebulizer in cystic fibrosis. Hubert D; Leroy S; Nove-Josserand R; Murris-Espin M; Mely L; Dominique S; Delaisi B; Kho P; Kovarik JM J Cyst Fibros; 2009 Sep; 8(5):332-7. PubMed ID: 19651542 [TBL] [Abstract][Full Text] [Related]
28. Long-term efficacy and safety of aerosolized tobramycin 300 mg/4 ml in cystic fibrosis. Mazurek H; Chiron R; Kucerova T; Geidel C; Bolbas K; Chuchalin A; Blanco-Aparicio M; Santoro D; Varoli G; Zibellini M; Cicirello HG; Antipkin YG Pediatr Pulmonol; 2014 Nov; 49(11):1076-89. PubMed ID: 24464974 [TBL] [Abstract][Full Text] [Related]
29. Effect of antibiotic co-administration on young and mature biofilms of cystic fibrosis clinical isolates: the importance of the biofilm model. Tré-Hardy M; Macé C; El Manssouri N; Vanderbist F; Traore H; Devleeschouwer MJ Int J Antimicrob Agents; 2009 Jan; 33(1):40-5. PubMed ID: 18801647 [TBL] [Abstract][Full Text] [Related]
30. Antimicrobial use and Pseudomonas aeruginosa susceptibility profile in a cystic fibrosis centre. Manno G; Cruciani M; Romano L; Scapolan S; Mentasti M; Lorini R; Minicucci L Int J Antimicrob Agents; 2005 Mar; 25(3):193-7. PubMed ID: 15737511 [TBL] [Abstract][Full Text] [Related]
31. Comparison of two tobramycin nebuliser solutions: pharmacokinetic, efficacy and safety profiles of T100 and TNS. Sands D; Sapiejka E; Gąszczyk G; Mazurek H; J Cyst Fibros; 2014 Dec; 13(6):653-60. PubMed ID: 24836961 [TBL] [Abstract][Full Text] [Related]
32. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Ratjen F; Munck A; Kho P; Angyalosi G; Thorax; 2010 Apr; 65(4):286-91. PubMed ID: 19996339 [TBL] [Abstract][Full Text] [Related]
34. Tobramycin inhalation powder: a review of its use in the treatment of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis. McKeage K Drugs; 2013 Nov; 73(16):1815-27. PubMed ID: 24194436 [TBL] [Abstract][Full Text] [Related]
35. In vitro interactions of tobramycin with various nonantibiotics against Pseudomonas aeruginosa and Burkholderia cenocepacia. Treerat P; Widmer F; Middleton PG; Iredell J; George AM FEMS Microbiol Lett; 2008 Aug; 285(1):40-50. PubMed ID: 18513356 [TBL] [Abstract][Full Text] [Related]
36. In vitro activities of various antibiotics, alone and in combination with colistin methanesulfonate, against Pseudomonas aeruginosa strains isolated from cystic fibrosis patients. Güzel CB; Gerçeker AA Chemotherapy; 2008; 54(2):147-51. PubMed ID: 18322363 [TBL] [Abstract][Full Text] [Related]
37. Acute renal failure in cystic fibrosis: association with inhaled tobramycin therapy. Hoffmann IM; Rubin BK; Iskandar SS; Schechter MS; Nagaraj SK; Bitzan MM Pediatr Pulmonol; 2002 Nov; 34(5):375-7. PubMed ID: 12357482 [TBL] [Abstract][Full Text] [Related]
38. Post-antibiotic effect of colistin, alone and in combination with amikacin, on Pseudomonas aeruginosa strains isolated from cystic fibrosis patients. Bozkurt-Güzel C; Gerçeker AA J Antibiot (Tokyo); 2012 Feb; 65(2):83-6. PubMed ID: 22126897 [No Abstract] [Full Text] [Related]